Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Targeting the PI3K/AKT pathway for the treatment of prostate cancer Sarker D; Reid AH; Yap TA; de Bono JSClin Cancer Res 2009[Aug]; 15 (15): 4799-805Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase pathway is increasingly implicated in prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the rapidly evolving therapeutic implications of targeting it. In particular, we highlight the importance of the appropriate selection of agents and combinations, and the critical role of predictive and pharmocodynamic biomarkers.|Androgen Receptor Antagonists[MESH]|Chemokines/metabolism[MESH]|Humans[MESH]|Male[MESH]|Oncogene Proteins, Fusion/metabolism[MESH]|PTEN Phosphohydrolase/metabolism[MESH]|Phosphatidylinositol 3-Kinases/*metabolism[MESH]|Phosphoinositide-3 Kinase Inhibitors[MESH]|Prostatic Neoplasms/drug therapy/*metabolism[MESH]|Protein Kinase Inhibitors/pharmacology[MESH]|Proto-Oncogene Proteins c-akt/antagonists & inhibitors/*metabolism[MESH]|Receptors, Androgen/*metabolism[MESH]|Serine Endopeptidases/metabolism[MESH]|Signal Transduction/drug effects/physiology[MESH]|Trans-Activators/metabolism[MESH]|Transcriptional Regulator ERG[MESH] |